[18F]PI-2620 Phase 3 Histopathological Study

Description

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Conditions

Alzheimer Disease

Study Overview

Study Details

Study overview

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)

[18F]PI-2620 Phase 3 Histopathological Study

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Phoenix

Barrow Neurological Institute, Phoenix, Arizona, United States, 85013

Sun City

Banner Sun Health Research Institute, Sun City, Arizona, United States, 85352

Los Angeles

UC Los Angeles, Los Angeles, California, United States, 90095 - 7370

San Francisco

Sutter Health, San Francisco, California, United States, 94114

Hialeah

Galiz Research, Hialeah, Florida, United States, 33016

Jacksonville

UF College of Medicine - Jacksonville, Jacksonville, Florida, United States, 32209

Lady Lake

K2 Medical Research, Lady Lake, Florida, United States, 32159

Maitland

ClinCloud Research, Maitland, Florida, United States, 32751

Maitland

K2 Medical Research, Maitland, Florida, United States, 32751

Miami

Miami Jewish Health Systems, Miami, Florida, United States, 33137

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Males and females aged 50 years and over
  • 2. Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
  • 3. Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
  • 4. Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure
  • 1. Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
  • 2. Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically \> 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
  • 3. Have suspected encephalopathy due to alcoholism or end-stage liver disease
  • 4. Are known to have a Glomerular Filtration Rate below \< 15 mL/min
  • 5. Have received an investigational or approved therapy directly targeting amyloid or tau
  • 6. Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
  • 7. Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Life Molecular Imaging Ltd,

Alireza Atri, MD, PhD, PRINCIPAL_INVESTIGATOR, Banner Health

Andrew Stephens, MD, PhD, STUDY_DIRECTOR, Life Molecular Imaging

Study Record Dates

2026-03